Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Italian Multicenter Phase II Trial of Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study

NCT05554003 is registered in ClinicalTrials.gov with European Institute of Oncology as lead sponsor.

NCT NCT05554003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05554003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Italian Multicenter Phase II Trial of Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study
Lead sponsor
European Institute of Oncology
Phase
Phase 2
Overall status
Recruiting
Start date
January 14, 2022
Completion date
December 31, 2024
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy effect, frailty, neuroendocrine tumors